Open AccessMMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study
Author(s) -
Émeline Tabouret,
François Bertucci,
Jean Yves Pierga,
Thierry Petit,
Christelle Lévy,
Jean Marc Ferrero,
Mario Campone,
Joseph Gligorov,
Florence Lerebours,
Henri Roché,
Thomas Bachelot,
Steven Van Laere,
Naoto T. Ueno,
Yves Toiron,
Pascal Finetti,
Daniel Birnbaum,
Jean-Paul Borg,
Patrice Viens,
Olivier Chinot,
Anthony Gonçalvès
Publication year - 2016
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.7612
Subject(s) - medicine , breast cancer , cancer , oncology , family medicine
Addition of bevacizumab to trastuzumab-based neoadjuvant chemotherapy in HER2-positive inflammatory breast cancer (IBC) was associated with favorable outcome in the BEVERLY-2 phase II trial. Circulating levels of matrix metalloproteinases (MMP) 2 and 9 were correlated to high response rate and prolonged survival in high-grade glioma treated with bevacizumab. We examined the prognostic impact of MMP2 and MMP9 serum levels in BEVERLY-2 patients.